“The Prescription of Dependency: Analyzing India’s Pharmaceutical Paradox, Supply-Chain Vulnerabilities, and the Direct Impact on Public Health Welfare”

Abstract

This paper analyzes the structural paradox within the Indian pharmaceutical industry, evaluating how downstream manufacturing dominance contrasts with deep upstream supply-chain vulnerabilities, and assesses the subsequent socio-economic impacts on public health welfare. Recognized globally as the "Pharmacy of the World," India ranks third in pharmaceutical production volume and supplies over 20% of global generic medications. However, a vertical audit of the sector's value chain reveals a critical dependency: Indian formulation hubs rely on a single external market—primarily China—for 70% to 85% of their Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs), leaving the industry exposed to external regulatory pauses, trade friction, and input price volatility. This study examines the human and economic costs of this dependency, tracing how international input cost shocks pass directly to the domestic population. In an economic landscape where Out-ofPocket Expenditure (OOPE) represents a significant portion of healthcare delivery, and where medicines constitute up to 70% of those individual expenses, supply-chain vulnerabilities create immediate financial strain for citizens managing chronic health conditions. Furthermore, the paper examines the fragmented nature of state and central regulatory enforcement and evaluates the defensive policy frameworks designed to reclaim health sovereignty. Specifically, the study audits the deployment of the state-backed Production Linked Incentive (PLI) schemes for bulk drugs, the infrastructure co-funding of Bulk Drug Mega Parks, and the retail price interventions enforced by the National Pharmaceutical Pricing Authority (NPPA) via the National List of Essential Medicines (NLEM). The paper concludes by presenting a strategic framework for shifting the industrial paradigm away from volatile, short-term cost optimization toward a resilient, vertically integrated model that secures long-term healthcare stability.